GALECTIN THERAPEUTICS INC — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Galectin Therapeutics' Chairman Richard Uihlein converted $105.8M in debt ($91.0M principal + $14.8M accrued interest) into 34,376,167 common shares, effective July 31, 2026, eliminating five of six credit facilities. Simultaneously, the FDA agreed on Phase 3 trial design for belapectin in MASH cirrhosis with portal hypertension; the company expects to submit the registrational protocol in Q3 2026. Cash position: $13.2M as of June 30, 2026, with $10M additional credit available.
Why this rating
Debt elimination ($105.8M ≈ 97% of market cap) is transformational for balance sheet; resolves solvency risk. FDA alignment de-risks Phase 3 pathway. Offset by massive dilution (34.4M shares issued) and continued cash burn ($9.2M Q2 loss).
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.